Liposomal daunorubicin and cytarabine is a formulation of the two drugs contained in tiny fat droplets called ‘liposomes’.
This new drug formulation, known as VyxoesÒ (Jazz Pharmaceuticals), has demonstrated superior efficacy to that of the two drugs given separately. The reasons for this are:
The liposomes protect the drugs from being broken down early so they remain in the body longer.
The liposomes are thought to build up in the bone marrow and enhance their effect on leukaemia cells.
Vyxoes is approved for the treatment of adults with newly-diagnosed AML , and has also been recommended by NICE for patients with untreated AML.
